#Israel #TopGum #Ramat Gan #Pharmaceutical Gummies #PL Developments

TopGum Expands U.S. Presence with Bold Acquisition

On May 5, 2026, TopGum Industries Ltd., a frontrunner in the gummy-format dietary supplement sector, finalized its acquisition of PL Developments LLC, a notable U.S. over-the-counter pharmaceuticals manufacturer. Valued at up to $35 million, this acquisition marks a significant step for TopGum as it pushes deeper into the U.S. market and ventures into the burgeoning pharmaceutical gummy sector. The deal, first announced through a formal letter of intent in January 2026, facilitates a strategic partnership in which PL Developments will handle the commercialization of TopGum's products through leading U.S. retailers under store-brand labels.

This acquisition not only strengthens TopGum's foothold in its largest market but also enhances its capacity as a pioneer within the pharmaceutical gummies space. TopGum now boasts a manufacturing base compliant with FDA standards, specifically tailored for producing both pharmaceutical and dietary supplement gummies. This state-of-the-art facility is among the few globally to achieve operational capabilities for manufacturing pharmaceutical gummies, setting the stage for significant growth.

The Strategic Implications of the Acquisition

The merger combines TopGum's innovative expertise with PLD's substantial manufacturing operations, directly addressing pressing shifts within the U.S. consumer health market. There is a growing trend towards gummies as a preferred dosage form for both vitamins, minerals, and supplements (VMS) and pharmaceutical products among consumers. Retailers have increasingly demanded local U.S.-based supply chains, which this acquisition effectively answers.

TopGum anticipates that the pharmaceutical gummy market will experience growth similar to the trajectory of dietary supplements over the past 15 years, where gummy formats became a leading choice. From this merger, TopGum can leverage its strategic advantages:

• - Innovative Leadership: TopGum solidifies its position as an innovative leader, pioneering the pharmaceutical gummy sector.
• - Manufacturing Clout: Establishing a U.S. manufacturing presence will shorten delivery times and better serve TopGum’s largest customer base.
• - Capacity for Growth: The existing infrastructure can easily accommodate a significant increase in production capacity without requiring substantial additional investment.
• - Global Reach: The combined state-of-the-art facilities situated in Israel, Canada, and now the U.S. create a robust global manufacturing platform.

For PL Developments, this transaction allows for a strategic redeployment of their manufacturing asset while ensuring both quality preservation and an expansion of their capacity to deliver premium gummy products. Additionally, PLD will gain privileged access to TopGum’s development pipeline, amplifying their market competitiveness.

Partnership Opportunities

Alongside the acquisition, TopGum and PLD are joining forces in a long-term strategic partnership aimed at commercializing TopGum's extensive portfolio of pharmaceutical and dietary supplement gummies. PLD's established connections in retail will help in effectively marketing these products, hence meeting the growing consumer demand for alternative dosage forms.

Eyal Shohat, CEO of TopGum, remarked on the strategic nature of this deal, emphasizing the significant role it plays in solidifying TopGum's presence as a key innovator in the space. Furthermore, the expected contribution from the transaction reflects a shared vision for growth and success between the two companies.

Evan Singer, President of PLD, emphasized that the gummy format provides an emerging platform for effective healthcare delivery, making this acquisition not only timely but essential in responding to consumer preferences.

Future Growth and Products

The newly acquired operation has an exciting pipeline that includes both dietary supplements and pharmaceutical gummies—many of which are nearing market launch. In collaboration with major pharmaceutical companies, TopGum is advancing products under FDA regulations. The anticipated launch of several pharmaceutical gummy products is scheduled for 2027 and 2028, with TopGum stepping in as the exclusive manufacturer.

Additionally, TopGum is considering further certifications for the facility under various regulatory bodies, paving the way for broader market access, including Australian markets.

Transaction Financials: The acquisition consideration includes a $10 million cash payment upon closing, along with shares valued at approximately $8 million, and additional share milestones of up to $17 million based on the achievement of commercial target objectives. PL Development stands to become a significant shareholder of TopGum, holding approximately 4% of the company’s equity following full diluted execution.

Looking Ahead

As TopGum integrates PL Developments' operations within its North American framework, the company envisions 2026 as a foundational transition year. The expected revenue from the acquired business is projected to reflect low single-digit millions, with a temporary negative EBITDA margin. However, as the integration solidifies, TopGum anticipates a return to profitability and growth in subsequent years.

Founded in 2004, TopGum remains committed to advancing health and wellness through innovative gummy products, and with the completion of this acquisition, they’ve set the stage for continued expansion and leadership in the healthcare sector. With comprehensive resources across Israel, Canada, and the United States, TopGum is poised to redefine the future of dietary and pharmaceutical supplements.